| Preferred Name |
Adalimumab |
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C65216 |
| Accepted_Therapeutic_Use_For |
Rheumatoid Arthritis, Crohn's Disease, Ankylosing Spondylitis, Psoriatic Arthritis |
| CAS_Registry |
331731-18-1 |
| code |
C65216 |
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173381 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173383 |
| Contributing_Source |
CTRP FDA |
| DEFINITION |
A recombinant, human IgG1 monoclonal antibody directed against tumor necrosis factor-alpha (TNF-alpha), with immunomodulating activity. Upon administration, adalimumab binds to TNF-alpha, thereby preventing its binding to the p55 and p75 TNF cell surface receptors and inhibiting TNF-mediated immune responses. TNF-alpha, a pro-inflammatory cytokine, is upregulated in various autoimmune diseases. |
| Display_Name |
Adalimumab |
| FDA_UNII_Code |
FYS6T7F842 |
| FULL_SYN |
ADALIMUMAB Adalimumab Immunoglobulin G1, anti-(human tumor necrosis factor) (human monoclonal D2E7 heavy chain), disulfide with human monoclonal D2E7 light chain, dimer LU200134 D2E7 Humira Adalimumab Biosimilar ABP 501 ABP 501 |
| label |
Adalimumab |
| Legacy Concept Name |
Adalimumab |
| NCI_Drug_Dictionary_ID |
791684 |
| PDQ_Closed_Trial_Search_ID |
791684 |
| PDQ_Open_Trial_Search_ID |
791684 |
| Preferred_Name |
Adalimumab |
| prefixIRI |
Thesaurus:C65216 |
| prefLabel |
Adalimumab |
| Semantic_Type |
Pharmacologic Substance |
| UMLS_CUI |
C1122087 |
| subClassOf |